The poster presentations will highlight Domain's progress in leveraging GPCR-targeting therapies to ... DT-7012 – A Differentiated CCR8-Depleting Antibody for Solid Tumors DT-7012 is a highly ...

Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades ...

Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...

The poster presentations will highlight Domain's progress in leveraging GPCR-targeting therapies to modulate the tumor microenvironment and enhance anti-cancer immune responses. DT-7012 – A ...